It was the aim of this investigation to determine whether or not covalent binding of di (2-ethylhexyl) phthalate (DEHP) to rat liver DNA could be a mechanism of action contributing to the observed induction of liver tumors after lifetime feeding of rodents with high doses of DEHP. DEHP radiolabeled in different positions was administered orally to female F344 rats with or without pretreatment for 4 weeks with 1% unlabeled DEHP in the diet. Liver DNA was isolated after 16 hr and analyzed for radioactivity. the DNA. HPLC analysis of enzyme-degraded DNA revealed that the normal nucleosides had incorporated radiolabel whereas no radioactivity was detectable in those fractions where the carcinogen-modified nucleoside adducts are expected. A quantitative evaluation of the negative data in terms of a limit of detection for a covalent binding index (CBI) indicates that covalent interaction with DNA is highly unlikely to be the mode of tumorigenic action of DEHP in rodents.
Introduction
Covalent binding of reactive metabolites of organic chemicals to DNA in the target cell is an important early event in the carcinogenicity of a large number of carcinogens. This interaction can have a number of mutational consequences so that many short-term tests on mutagenicity can be used for a qualitative screening of chemicals for DNA interactions. The amount of carcinogen bound to DNA is dependent on a variety of parameters, such as the concentration at the site of metabolism, the rate of enzymatic activation and of enzymatic and nonenzymatic inactivation reactions, the diffusion to the critical DNA target, and the reactivity towards nucleic acids as opposed to other nucleophiles. Because of the complexity of these in part competing processes carcinogenicity, while a CBI of around 100 is found with moderate carcinogens and of 1 to 10 for weak carcinogens (3). This correlation also means that chemicals with a CBI of less than 0.1 are highly unlikely to give rise to a carcinogenicity detectable in a long-term bioassay unless they have, in addition to a minute DNA binding activity, some cocarcinogenic or promoting activity (4).
The possibility for such a distinction between DNA binding on the one hand and other mechanisms on the other hand in the process of tumor formation was the reason for the interest in performing DNA-binding assays in vivo with compounds which gave rise to an increased tumor incidence in a rodent bioassay. The idea behind it was the understanding that an extrapolation to low doses to which man is exposed will be linear for the formation of DNA-carcinogen adducts, while nonlinearities and possibly thresholds could be expected for the low-dose extrapolations with other mechanisms of carcinogenic action.
With the use of radiolabeled test compound for a DNAbinding study, only those nucleotide-carcinogen adducts are detectable which still carry the radiolabel. Since DEHP is composed of essentially two structural elements, the phthalic acid and the alcohol, differently marked DEHP molecules (I-IV) were used ( Fig. 1) .
The long-term exposure to DEHP used in the carcinogenicity studies could have induced qualitative and/or quantitative changes in the enzymatic drug metabolism pattern. In animals was pretreated for 4 weeks with a diet containing 10 g/kg DEHP (1%).
Methods and Materials
A detailed report on this study has recently been pub- hr, the animals were killed with ether, the liver was excised and homogenized immediately, and a crude chromatin fraction was prepared. DNA was purified by extractions of the chromatin, hydroxyapatite adsorption chromatography, dialysis, and precipitation with ethanol.
DNA was degraded with DNAase, phosphodiesterase, and alkaline phosphatase to the deoxyribonucleosides, or with hydrochloric acid to the purine bases and apurinic acid. Separation of the DNA constituents was performed with reverse-phase HPLC. The specific activities determined for the DNA samples were expressed in the units of the covalent binding index (CBI), in order to allow a quantitative comparison with other carcinogens and noncarcinogens (1).
Results

Total DNA Radioactivity
After the administration of carboxylate-labeled DEHP I, a minute amount of radioactivity could be detected in only one out of four DNA samples. In all other samples, irrespective of the DEHP pretreatment, the radioactivity was below the limit of detection of the order of 0.02 CBI units. When the label was in the alcohol moiety (DEHP II and III), DNA radioactivity was easily detected in all cases, regardless of whether the label was It could be shown that the normal nucleosides were radiolabeled, whereas no radiolabel was detectable in those fractions which nornally contain the more lipophilic DNA-carcinogen adducts. After deduction of this anabolic incorporation of radiolabel from the original (total) specific activity of DNA, maximum possible CBI values of 0.1 to 0.5 and 0.6 to 0.9 resulted for DEHP II and EH IV, respectively, while the tritium data from DEHP III gave an upper bound of 0.2 to 0.3 for true covalent binding.
Another way of estimating maximum possible CBI could be based upon the general assumption that carcinogen-deoxyribonucleoside adducts are expected to elute after the normal constituents due to a higher lipophilicity of such adducts. No radioactivity could be detected in this region. On the basis of the standard deviation of the background radioactivity determined from a DNA sample isolated from an untreated animal, a limit of detection for a possible carcinogen-deoxyribonucleoside adduct was calculated. The maximum CBI of DEHP 
Discussion
The results show that a covalent binding of DEHP to rat liver DNA must be below a CBI value of 0.05. This upper bound is 200,000 times below the CBI for the potent hepatocarcinogen aflatoxin B1 and 20 to 200 times below the CBI of weakly DNA-binding carcinogens, where very large daily doses are required to produce an increase in tumor-bearing animals in a standard long-term bioassay.
The negative binding data derived from these experiments with DEHP therefore suggest that the tumorigenicity of this compound was probably due to a mode of action not related to DNA binding. In such a situation, tumor induction could go in parallel with some type of biological response-possibly species specific-which might also be observable in the long-term bioassay. Most of these biological responses are expected to follow the sigmoid dose-effect relationship generally known from other pharmacological activities. Such a mechanism might therefore allow the consideration of a threshold and it will be most important to search for other effects of DEHP on the animals' biology and find out whether the processes which parallel the induction of tumors in the bioassay are also found in humans exposed to much lower doses.
